Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical

- Closes $7.5 Million Second Tranche Investment from DaVita -  $30 Million in Total Capital Raised This Quarter - Receives Additional Feedback from FDA on its IND Application WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients, today provided an update on its recent capital raise and a clinical update on safety enhancements to its planned Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) in home infusion patients.

Rockwell Medical Provides Corporate and Clinical Update

DENVER , June 22, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today it will hold a special conference call with investors on Thursday, June 23, 2022, at 8:45 a.m. Eastern Time.

DaVita Inc. Schedules Special Investor Conference Call

The U.S. Supreme Court on Tuesday rejected kidney dialysis provider DaVita Inc's claims that an Ohio hospital's employee health plan discriminates against patients with end-stage renal disease by reimbursing them at low rates in hopes they would switch to Medicare.

U.S. Supreme Court rules against DaVita over dialysis coverage

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

Here's Why You Should Hold on to DaVita (DVA) Stock For Now

RadNet

U.S. Physical Therapy

Despite the COVID-19 pandemic-induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.

3 Stocks to Watch From a Buoyant Outpatient Home Health Industry

Medtronic

Medtronic plc (NYSE: MDT) and DaVita Inc (NYSE: DVA) intend to form a new, independent kidney care-focused medical device company (NewCo). NewCo will focus on developing a broad suite of novel kidney care products and solutions, including future home-based products.

Medtronic, DaVita To Jointly Form Kidney Health-Focused Company

Companies join forces to accelerate kidney care device innovation and improve patient outcomes DUBLIN and DENVER, May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) and DaVita Inc. (NYSE:DVA) today announced the intent to form a new, independent kidney care-focused medical device company ("NewCo" or "the Company") to enhance the patient treatment experience and improve overall outcomes. By bringing together Medtronic's capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider, NewCo will be uniquely positioned to advance the development of differentiated therapies for patients with kidney failure.

Medtronic and DaVita announce new kidney health technology company

Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now

With steady revenues and a predictable earnings profile, DaVita is a perfect example of a stock which could add stability to investors' portfolios during periods of volatility. While the company has a hefty debt load, the company's maturity schedule and cash flow offer management a lot of flexibility, addressing the larger near-term maturities in 2024 and 2026.

DaVita Offers Stability During Market Volatility

SAN FRANCISCO--(BUSINESS WIRE)--Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the implementation of its flagship personalized dosing product at DaVita (NYSE: DVA) clinics nationwide. Dosis's Smart Anemia Manager (SAM) personalizes drug dosing for erythropoiesis-stimulating agents (ESAs), a class of drugs used to treat end-stage renal disease patients with chronic anemia. Integration of Dosis's personalized dosing recommendations into DaVita's anemia

Dosis Announces Nationwide Precision Dosing Implementation with DaVita

Recognizes nurses who make an exceptional difference in care delivery. DENVER , May 10, 2022 /PRNewswire/ -- DaVita  today announced that 56 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week.

DaVita Honors Extraordinary Nurses with DAISY Awards

DENVER , May 9, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat with investors at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 11 a.m. EDT. To view the live webcast, visit the Bank of America Securities page and create a free registration.

DaVita Inc. to Participate in the Bank of America Securities 2022 Healthcare Conference

Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.

DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View

Bank of America

Twenty-First Century Fox

Labcorp Holdings Inc

Netflix

Southern Copper

Consider these seven oversold stocks, as fear, uncertainty and doubt have knocked them down to too low a price. The post 7 Oversold Stocks That Shouldn't Be.

7 Oversold Stocks That Shouldn't Be. Buy Them Now.

DaVita Inc. (NYSE:DVA ) Q1 2022 Results Conference Call May 5, 2022 5:00 PM ET Company Participants Joel Ackerman - CFO and Treasurer Javier Rodriguez - CEO Conference Call Participants Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Pito Chickering - Deutsche Bank Operator Good evening. My name is Missy, and I'll be your conference facilitator today.

DaVita Inc. (DVA) CEO Javier Rodriguez on Q1 2022 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.97% and 2.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Q1 Earnings and Revenues Lag Estimates

DaVita Inc. shares dropped in the extended session Thursday after the dialysis-service provider's earnings fell short of Wall Street estimates as the company said COVID-19 factors and higher wages dinged its bottom line.

Earnings Results: DaVita stock falls as higher wages, missed treatments push earnings below Street expectations

DENVER , May 5, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2022. For the quarter, diluted earnings per share was $1.61, a decrease of (10.1)% from the prior quarter.

DaVita Inc. 1st Quarter 2022 Results

Shares progress made toward its vision for global corporate citizenship. DENVER , May 3, 2022 /PRNewswire/ -- Today, DaVita Inc. highlighted its continued commitment to corporate citizenship with the publication of its annual Community Care Environmental Social Governance (ESG) Report.

DaVita Celebrates 2021 ESG, Corporate Social Responsibility Achievements

Bank of New York Mellon

Globe Life Inc

Wells Fargo

Investors around the world are making the journey to Omaha, Nebraska to attend Berkshire Hathaway's ( BRK.A , Financial)( BRK.B , Financial) annual shareholder meeting this weekend, which is being held in person for the first time in two years.

5 Undervalued Buffett Stocks Ahead of Annual Meeting

DENVER , April 21, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 5, 2022, at 5 p.m. Eastern Time.

DaVita Inc. Schedules 1st Quarter 2022 Investor Conference Call

A jury in Denver, Colorado, acquitted dialysis provider DaVita and its former CEO Kent Thiry on Friday of charges that they conspired with competitors not to hire each other's employees.

DaVita and its former CEO acquitted of antitrust charges

$7.5M initial equity investment in Rockwell Amended and expanded supply agreement Strengthens Rockwell's financial position, laying groundwork for improved concentrate business WIXOM, Mich., April 11, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced an expanded partnership with DaVita Inc. (NYSE: DVA), a leading kidney care provider.

Rockwell Medical Expands Partnership with DaVita

DENVER , April 7, 2022 /PRNewswire/ -- DaVita Inc. announced today that its board of directors appointed a new independent director, Jason M. Hollar, to join the board, effective May 6, 2022.

DaVita Announces Jason M. Hollar to Join its Board of Directors

Results demonstrate the importance of vaccinating patients at trusted sites of care DENVER and WALTHAM, Mass. , April 4, 2022 /PRNewswire/ -- A federal partnership established to help increase access to COVID-19 vaccines for end stage kidney disease (ESKD) patients receiving dialysis was successful in reducing racial disparities in vaccination coverage, new research published today in JAMA Internal Medicine affirms.

News for DaVita Stock (DVA)